Ind-Swift Laboratories to upgrade Samba facility with investment of Rs 40 crore

16 Feb 2026 Evaluate

Ind-Swift Laboratories has approved a capital investment of around Rs 40 crore to upgrade its finished dosage manufacturing facility located at Samba, Jammu & Kashmir. With this investment, the facility will be enhanced to meet international regulatory standards, primarily EU-GMP and PIC/S, enabling the site to cater to regulated export markets.

Proposed enhancements will improve environmental sustainability, strengthen material governance, and enhance utility reliability across the facility. The company assumes to complete this upgradation within a span of 8-12 months. Upon completion, the company envisages to receive EU GMP approval within 8-9 months & plans to simultaneously file around 15-20 molecules across Europe & UK, Australia, Canada and South Africa.

The existing ointment section is currently catering to the domestic market which includes manufacturing of own brands, contract manufacturing. Other dosage forms like tablets, capsules, dry syrups are also supplied from this facility. The unit generates an annual sales of Rs 36 crore with a bottom line of an average 10%. 

Ind-Swift Laboratories is global manufacturer of APIs, Intermediates and formulations (through group collaboration). 


Ind-Swift Lab. Share Price

143.60 0.00 (0.00%)
17-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.40
Dr. Reddys Lab 1285.00
Cipla 1343.35
Zydus Lifesciences 906.75
Lupin 2247.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×